SecBot SecBot
SECBOTREPLAY Home › Report › REPL

REPL · Replimune reported a modest EPS beat ($-0.72 vs $-0.77 consensus) for…

Replimune, Inc. · PRESS-RELEASE filed Aug 14, 2026 at 08:00 ET

At the news

BULLISHIMPACT 7/10

PRESS-RELEASE filed Aug 14, 2026 at 08:00 ET

Replimune reported a modest EPS beat ($-0.72 vs $-0.77 consensus) for Q1 FY2026, but the headline is the FDA accelerated approval of TUDRIQEV (RP1) for advanced melanoma, announced August 6, 2026. The company is launching within 60 days, recently completed a $150M offering to fund commercialization, and appointed a new CCO. The approval transforms Replimune into a commercial-stage biotech, though the dilutive offering and need for confirmatory trial data temper the outlook.

  • FDA accelerated approval of TUDRIQEV (RP1) + nivolumab for advanced melanoma on August 6, 2026; launch within 60 days
  • Q1 FY2026 EPS $-0.72 beat consensus $-0.77 by 6.5%; net loss improved to $69.8M from $86.7M YoY
  • Cash, equivalents & short-term investments $195.3M at June 30, 2026; plus $141M net proceeds from August offering extends runway >12 months
  • Appointed Michelle DiNapoli as Chief Commercial Officer, effective August 18, 2026

Replay the market's reaction

Step through every 5 minutes around the news, then see how it compares with similar events.

Subscribe for Full Access